inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
Company profile
Ticker
INM
Exchange
Website
CEO
Eric Adams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biogen Sciences Inc. • Sweetnam Consulting Inc. • InMed Pharmaceuticals Ltd. • BayMedica, LLC ...
INM stock data
Latest filings (excl ownership)
8-K
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
20 Mar 24
8-K
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
13 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
8-K
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
9 Feb 24
8-K
Regulation FD Disclosure
19 Jan 24
8-K
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
16 Jan 24
S-8
Registration of securities for employees
21 Dec 23
10-K/A
2023 FY
Annual report (amended)
21 Dec 23
8-K
InMed Announces Results of 2023 Annual General Meeting
19 Dec 23
8-K
Regulation FD Disclosure
29 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.74 mm | 6.74 mm | 6.74 mm | 6.74 mm | 6.74 mm | 6.74 mm |
Cash burn (monthly) | 724.74 k | 217.68 k | 845.61 k | 581.19 k | 724.74 k | 600.16 k |
Cash used (since last report) | 4.34 mm | 1.30 mm | 5.06 mm | 3.48 mm | 4.34 mm | 3.59 mm |
Cash remaining | 2.40 mm | 5.44 mm | 1.68 mm | 3.26 mm | 2.40 mm | 3.15 mm |
Runway (months of cash) | 3.3 | 25.0 | 2.0 | 5.6 | 3.3 | 5.2 |
Institutional ownership, Q3 2023
0.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 18.54 mm |
Total shares | 26.87 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Susquehanna International | 26.59 k | $18.35 mm |
TD Waterhouse Canada | 85.00 | $76.00 k |
UBS UBS Group AG - Registered Shares | 69.00 | $48.00 k |
Advisor | 61.00 | $40.00 k |
RY Royal Bank Of Canada | 26.00 | $0.00 |
AllSquare Wealth Management | 21.00 | $14.00 k |
National Bank of Canada | 20.00 | $13.00 k |
TD Toronto Dominion Bank | 2.00 | $1.00 k |
Gables Capital Management | 1.00 | $1.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Eric C Hsu | Employee Stock Option (Expiration) Common shares | Dispose H | No | No | 364.72 | 309 | 112.70 k | 52,545 | |
21 Feb 24 | Andrew Hull | Common Stock | Buy | Acquire P | No | No | 0.39 | 37,500 | 14.63 k | 38,258 |
20 Feb 24 | Eric A Adams | Common Stock | Buy | Acquire P | No | No | 0.3587 | 41,600 | 14.92 k | 43,959 |
21 Jan 24 | Alexandra Diane Janet Mancini | Employee Stock Option (Expiration) Common shares | Dispose H | No | No | 312.73 | 121 | 37.84 k | 52,485 |
News
InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/098,324 Titled "Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders"
7 Mar 24
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
23 Feb 24
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
22 Feb 24